Updated: Feb 15, 2022
Now is the time to assess financial readiness for the upcoming year. What questions are you asking?
Friday, November 19, 12:00 - 12:45 PM EST
As the fall leaves commence their colorful journey to winter, finance and accounting professionals focus on getting next year's budget ready and preparing for an audit of the current year's results. The fall is a time for the company to assess where they are internally, and the capital-needs outlook for the organization.
Are you ready for the financial reviews demanded over the next few months? Here are some typical questions you may be exploring:
Should we stay private or explore going public?
What type of audit standard will we need in the coming year, AICPA or PCAOB?
Have the financials been reconciled?
Have contracts executed during the year been accounted for properly?
Is the capitalization table up to date?
Have stock-based compensation plans been completed?
Is a new 409a needed to account for changes in valuation during the year or to provide year-end employee equity grants?
Are all equity instruments (convertible debt, stock options, warrants, etc.) recorded correctly with technical memos to support accounting positions taken?
Do we have documented financial controls, and have they been internally documented and tested?
Has turnover and resignations caught the company without enough internal finance and accounting resources to finish the year and be ready for spring?
Are you ready for tax season or want to chart a tax strategy course for the coming year.
Kevin Sarney Charles River CFO, Life Sciences Practice Leader
Kevin leads our Life Sciences Practice and serves in a CFO role for our clients. With over 20 years of experience in public and private life science companies and professional services. He utilizes his experiences to assist companies in the preparation and completion of financial raises, public company readiness, financial controls, audits, SEC reporting and supporting financial operations from drug development through pharmaceutical product launches.
Kevin’s professional career began in Big 4 public accounting. He has held leadership positions at public biotech companies and private early-stage drug development companies. Kevin has numerous experiences in assisting companies going public at Enumeral, Tesaro, Tetraphase, Karyopharm, and Genocea. Kevin earned a B.S. in business management from the University of Hartford, an MBA from Boston University, and an M.A. in accounting from Suffolk University. Kevin is a CPA in Massachusetts.
Thomas Frisiello, CPA, MSA
The MFA Companies, Director
Mr. Frisiello’s audit experience includes a wide range of complex privately-held and publicly-traded enterprises. He specializes in manufacturing and emerging growth industries and has successfully completed engagements for manufacturing, distribution, software, technology, professional services and nonprofit customers.
Thomas’ expertise includes experience with technical accounting subjects such as revenue recognition, share based payments, stock-based compensation and complex debt and equity transactions. In his role at The MFA Companies®, he works closely with customers, assisting them in meeting filing requirements, performing audits,
reviews, compilations, agreed-upon procedures and other attestation services.
Prior to MFA, Thomas worked for a Boston-area CPA firm as a senior accountant. During this time, he performed a wide variety of audits and also prepared tax returns for corporate entities, partnerships and nonprofit organizations.